Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. [electronic resource]
Producer: 20150406Description: 510-4 p. digitalISSN:- 1476-5551
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis
- Benzamides -- administration & dosage
- Boronic Acids -- administration & dosage
- Bortezomib
- Cell Line
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Drug Screening Assays, Antitumor
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Mice
- Mice, SCID
- Monomeric GTP-Binding Proteins -- metabolism
- Multiple Myeloma -- drug therapy
- Mutation
- Neoplasm Transplantation
- Pyrazines -- administration & dosage
- Pyrazoles -- administration & dosage
- Retinal Pigment Epithelium -- cytology
No physical items for this record
Publication Type: Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.